The incidence of osimertinib-associated grade 3 or higher cardiac adverse events was 4.9% in a retrospective NSCLC population.
A phase 3 trial of elderly patients with nonsquamous NSCLC demonstrated that carboplatin + pemetrexed prolonged survival with an improved safety profile compared with docetaxel.
Neoadjuvant chemotherapy was found to negatively impact survival in resectable malignant pleural mesothelioma.
The researchers noted that medical distancing for those with cancer could help prevent the spread of the virus in this highly vulnerable population.
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
The patient recovered from pneumonia and stable disease was observed.
Nonsignificant variation of acquired resistance occurred by drug type.
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
57 percent have spirometry findings consistent with COPD, 67 percent do not have prior history of COPD.
Optimal combinations of MEK, ROS1 inhibitors should be explored.
The FDA has granted Breakthrough Therapy designation to JNJ-6372 (Janssen) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
Despite California’s legal cannabis market, 75% of products that contained THC were obtained from informal sources.
Testing only occurred among symptomatic patients.
Brigatinib is associated with the longest PFS of any ALK inhibitor in patients with ALK-positive NSCLC following disease progression on crizotinib, according to a study.
Updated data from KEYNOTE-010 showed superior outcomes for pembrolizumab compared with docetaxel in patients with PD-L1‒expressing advanced NSCLC.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
12.5 percent of those meeting USPSTF recommendations for low-dose CT had screening exam in past year.